ED24HDQ0G0400
Project Grant
Overview
Grant Description
Purpose: The Oncology Clinical Decision Support for Data-Centric Treatment project is spearheaded by GE Healthcare (GEHC).
This project's goals are twofold: (1) to increase the application and adoption of personalized medicine like theranostics by equipping clinicians with a theranostics toolkit software which helps them leverage the latest treatments and technologies, and (2) to help drive local production of radioisotopes by providing insights that will prepare manufacturers and supply chains to meet rising demand.
As part of the Wisconsin Biohealth Tech Hub, this provides an opportunity to utilize specific cancer use cases to prove this concept and extrapolate the benefits of scaling the approach to other regions and complex "-ologies" (cardiology, neurology).
By extending to other diseases and pharmaceuticals, Wisconsin has the potential to become a leading force in precision medicine globally.
Activities to be performed:
Hire program leads and key staff to kickoff project.
Deploy, integrate and enable theranostics toolkit readiness at key sites.
Map, measure and baseline oncology/theranostic workflows.
Demonstrate and measure the impact of the theranostics toolkit including theranostic candidate evaluation, AI model deployment, and integrating workflow specific oncology alerts based on cancer guidelines.
Leverage impact insights to realize benefits and prepare for expansion.
Expected outcomes:
Greater than 71% less time and >71% simplified manual workflow for patient/MDT preparation suggests greater patient capacity, potential throughput.
83% less time and 100% simplified manual workflow to pre-screen for clinical trials suggests greater theranostics patient identification and clinical trial matching.
Clinicians expect 92% expect more workflow capacity; 100% expect more confidence; 85% expect better decision making by having all available data in one place suggests higher demand for therapies and scans.
Intended beneficiaries: Healthcare AI companies and job-seekers (WI residents and non-residents) who can deploy their AI models via the theranostics toolkit platform including oncology patients aiming to reenter the workforce (and associated places of work).
By leveraging data from CareScan, the toolkit will also enable insights and benefits around personalized medicine.
Other beneficiaries include healthcare systems seeking to optimize the patient journey, staff time, and processes to manage demand (e.g. vacancy rates for nurses started increasing in 2021 above 9.4%), pharmaceutical and supply chain companies that produce radioisotopes upon receiving timely, vetted theranostics and clinical trial candidate insights, and oncology therapy providers and their supply chain, including producers of lab materials, and the workforce performing the required clinical trials or scans.
Subrecipient activities:
University of Wisconsin, Madison - will serve as a site for integration and deployment of the GEHC theranostics toolkit.
Site persona will provide feedback and clinical/technical expertise around three new features, providing real-world data points derived from use of the toolkit within the oncology clinical workflow (this includes baselining and two evaluations leveraging the toolkit for 1+ use case, and potential reports, etc.).
They will also provide clinical and technical input around expansion to other disease states as well as clinical/economic downstream impact.
Personnel includes various clinicians and hospital persona (the users of the theranostics toolkit), project leads, a PI, and health IT for the solution integration and deployment.
Medical College of Wisconsin - will serve as a site for integration and deployment of the GEHC theranostics toolkit.
This project's goals are twofold: (1) to increase the application and adoption of personalized medicine like theranostics by equipping clinicians with a theranostics toolkit software which helps them leverage the latest treatments and technologies, and (2) to help drive local production of radioisotopes by providing insights that will prepare manufacturers and supply chains to meet rising demand.
As part of the Wisconsin Biohealth Tech Hub, this provides an opportunity to utilize specific cancer use cases to prove this concept and extrapolate the benefits of scaling the approach to other regions and complex "-ologies" (cardiology, neurology).
By extending to other diseases and pharmaceuticals, Wisconsin has the potential to become a leading force in precision medicine globally.
Activities to be performed:
Hire program leads and key staff to kickoff project.
Deploy, integrate and enable theranostics toolkit readiness at key sites.
Map, measure and baseline oncology/theranostic workflows.
Demonstrate and measure the impact of the theranostics toolkit including theranostic candidate evaluation, AI model deployment, and integrating workflow specific oncology alerts based on cancer guidelines.
Leverage impact insights to realize benefits and prepare for expansion.
Expected outcomes:
Greater than 71% less time and >71% simplified manual workflow for patient/MDT preparation suggests greater patient capacity, potential throughput.
83% less time and 100% simplified manual workflow to pre-screen for clinical trials suggests greater theranostics patient identification and clinical trial matching.
Clinicians expect 92% expect more workflow capacity; 100% expect more confidence; 85% expect better decision making by having all available data in one place suggests higher demand for therapies and scans.
Intended beneficiaries: Healthcare AI companies and job-seekers (WI residents and non-residents) who can deploy their AI models via the theranostics toolkit platform including oncology patients aiming to reenter the workforce (and associated places of work).
By leveraging data from CareScan, the toolkit will also enable insights and benefits around personalized medicine.
Other beneficiaries include healthcare systems seeking to optimize the patient journey, staff time, and processes to manage demand (e.g. vacancy rates for nurses started increasing in 2021 above 9.4%), pharmaceutical and supply chain companies that produce radioisotopes upon receiving timely, vetted theranostics and clinical trial candidate insights, and oncology therapy providers and their supply chain, including producers of lab materials, and the workforce performing the required clinical trials or scans.
Subrecipient activities:
University of Wisconsin, Madison - will serve as a site for integration and deployment of the GEHC theranostics toolkit.
Site persona will provide feedback and clinical/technical expertise around three new features, providing real-world data points derived from use of the toolkit within the oncology clinical workflow (this includes baselining and two evaluations leveraging the toolkit for 1+ use case, and potential reports, etc.).
They will also provide clinical and technical input around expansion to other disease states as well as clinical/economic downstream impact.
Personnel includes various clinicians and hospital persona (the users of the theranostics toolkit), project leads, a PI, and health IT for the solution integration and deployment.
Medical College of Wisconsin - will serve as a site for integration and deployment of the GEHC theranostics toolkit.
Funding Goals
NON-CONSTRUCTION - FY23 REGIONAL TECHNOLOGY AND INNOVATION HUB PROGRAM PHASE 2
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Schenectady,
New York
12309-1027
United States
Geographic Scope
Single Zip Code
GE Medical Systems Information Technologies was awarded
Oncology Decision Support Project for Personalized Medicine
Project Grant ED24HDQ0G0400
worth $7,999,998
from Economic Development Administration in October 2024 with work to be completed primarily in Schenectady New York United States.
The grant
has a duration of 5 years and
was awarded through assistance program 11.039 Regional Technology and Innovation Hubs.
$6,715,590 (46.0%) of this Project Grant was funded by non-federal sources.
The Project Grant was awarded through grant opportunity FY 2023 Regional Technology and Innovation Hub Program Phase 2 Notice of Funding Opportunity.
Status
(Ongoing)
Last Modified 8/29/25
Period of Performance
10/1/24
Start Date
9/30/29
End Date
Funding Split
$8.0M
Federal Obligation
$6.7M
Non-Federal Obligation
$14.7M
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
ED24HDQ0G0400
SAI Number
None
Award ID URI
None
Awardee Classifications
For-Profit Organization (Other Than Small Business)
Awarding Office
1331K5 DEPT OF COMMERCE EDA
Funding Office
1331K5 DEPT OF COMMERCE EDA
Awardee UEI
G2JTZ3UQV9M3
Awardee CAGE
9G8T4
Performance District
NY-20
Senators
Kirsten Gillibrand
Charles Schumer
Charles Schumer
Modified: 8/29/25